mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000

View company profile
Please contact the Account Manager for opportunities with this organisation

Astellas and Theravance submit marketing application

Posted on 29/10/2009 in Pharmaceutical Company Product News

Astellas, in partnership with Theravance, has submitted a marketing authorisation application to the European Medicines Agency (EMEA) for the drug telavancin.

The bactericidal injectable lipogly copeptide antibiotic, designed to be taken once a day, is used for the treatment of nosocomial pneumonia, ventilator-associated pneumonia and complicated skin and soft tissue infections in adults.

It was developed by Theravance during a research programme conducted to find new antibiotics for serious infections brought about by Staphylococcus aureus and grampositive bacteria, such as MRSA.

Masao Yoshida, president and chief executive of Astellas, commented: "We look forward to working with the regulatory authorities and out parent, Theravance, to efficiently progress telavancin through the remaining steps to approval."

Earlier this month, Astellas revealed that the Food and Drug Administration has granted an additional six months of paediatric exclusivity for its Flomax (tamsulosin hydrochloride) capsules.

Other news stories from 29/10/2009

Read more in the Zenopa News Archive

How this news is generated

Jo-Anne
Account Manager
for this opportunity

01494 818 012
(Mon to Fri 0830 to 1800 hours)
jo@zenopa.com

Latest News

Astellas and UMN Pharma to develop new flu vaccines

Astellas agrees co-promotion deal for antibiotic Avelox

Astellas extends licensing deal for antibody technology

Astellas completes buyout of OSI Pharmaceuticals

Astellas agrees deal to buy OSI Pharmaceuticals

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use